De Bernardo Maddalena, Capasso Luigi, Lanza Michele, Tortori Antonia, Iaccarino Stefania, Cennamo Michela, Borrelli Maria, Rosa Nicola
Department of Medicine and Surgery, University of Salerno, Salerno, Italy.
U.O.C. Prelievo e Trapianto Cornee, Pellegrini Hospital, Naples, Italy.
J Optom. 2015 Jul-Sep;8(3):180-6. doi: 10.1016/j.optom.2014.05.006. Epub 2014 Jun 16.
To evaluate long-term keratoconus stability after corneal crosslinking (CXL) with riboflavin.
In this prospective study, 57 eyes of 55 patients with progressive keratoconus, consecutively treated with ultraviolet A (UVA) - riboflavin CXL, were examined with the corneal topographer Pentacam, the biometer IOLMaster and the analyzer of corneal biomechanics Ocular Response Analyzer before and during a 24 months follow-up after CXL.
Twenty-four months after CXL, there was a significant improvement in best corrected visual acuity (BCVA) (P<0.01), a significant decrease in corneal thinnest point (CTP), keratometry readings at the keratoconus apex (K max), and corneal volume (CV) (P<0.01), and a significant increase in axial eye length (AL) (P=0.01). No significant changes in anterior chamber volume (ACV) and depth (ACD), (P=0.8), corneal hysteresis (CH) (P=0.16) and corneal resistance factor (CRF) (P=0.06) were found. However, in the subgroup of patients with decreased K max readings 24 months after treatment, both CH and CRF showed a significant reduction (P<0.01).
In the first month after the procedure, CXL induces a reduction in corneal volume. During the 24 months follow-up the cornea tends to recover its original volume with a persistence of the CXL efficacy.
评估核黄素角膜交联术(CXL)后圆锥角膜的长期稳定性。
在这项前瞻性研究中,对55例进行性圆锥角膜患者的57只眼连续进行紫外线A(UVA)-核黄素CXL治疗,在CXL术前及术后24个月随访期间,使用角膜地形图仪Pentacam、生物测量仪IOLMaster和角膜生物力学分析仪眼反应分析仪(Ocular Response Analyzer)进行检查。
CXL术后24个月,最佳矫正视力(BCVA)显著改善(P<0.01),角膜最薄点(CTP)、圆锥角膜顶点角膜曲率读数(K max)和角膜体积(CV)显著降低(P<0.01),眼轴长度(AL)显著增加(P=0.01)。前房体积(ACV)和深度(ACD)(P=0.8)、角膜滞后(CH)(P=0.16)和角膜阻力因子(CRF)(P=0.06)无显著变化。然而,在治疗后24个月K max读数降低的患者亚组中,CH和CRF均显著降低(P<0.01)。
在手术后的第一个月,CXL导致角膜体积减小。在24个月的随访期间,角膜倾向于恢复其原始体积,同时CXL疗效持续存在。